| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR | ANN ARBOR | MI | 48108-9623 | WASHTENAW | USA | R44TR001324 | Fiber design and assessment for development of a novel biomimetic medical device | 000 | 4 | NIH | 11/19/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,314,026 ) |
| | 2024 | 2024 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR | ANN ARBOR | MI | 48108-9623 | WASHTENAW | USA | R44HL170779 | Cell Directed Immunomodulation Therapy as a Bridge to Left Ventricular Device Implantation in Chronic Heart Failure Patients | 000 | 1 | NIH | 4/24/2024 | $1,314,026 |
| | 2024 | 2022 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR | ANN ARBOR | MI | 48108-9623 | WASHTENAW | USA | R43HL164239 | SCD-PICC Therapy for Respiratory Insufficiency associated with COVID-19 in non-ICU settings | 000 | 1 | NIH | 3/8/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $6,500 ) |
| | 2023 | 2023 | INNOVATIVE BIO-THERAPIES INC | 650 AVIS DR | ANN ARBOR | MI | 48108-9623 | WASHTENAW | USA | R43HL164239 | SCD-PICC Therapy for Respiratory Insufficiency associated with COVID-19 in non-ICU settings | 000 | 1 | NIH | 2/17/2023 | $6,500 |
| | 2023 | 2022 | INNOVATIVE BIO-THERAPIES INC | 650 AVIS DR | ANN ARBOR | MI | 48108-9623 | WASHTENAW | USA | R44TR001324 | Fiber design and assessment for development of a novel biomimetic medical device | 000 | 4 | NIH | 4/13/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $878,556 ) |
| | 2022 | 2022 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR STE 300, | ANN ARBOR | MI | 48108-9623 | WASHTENAW | USA | R43HL164239 | SCD-PICC Therapy for Respiratory Insufficiency associated with COVID-19 in non-ICU settings | 000 | 1 | NIH | 8/12/2022 | $325,257 |
| | 2022 | 2022 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR STE 300, | ANN ARBOR | MI | 48108-9623 | WASHTENAW | USA | R44TR001324 | Fiber design and assessment for development of a novel biomimetic medical device | 000 | 4 | NIH | 8/1/2022 | $553,299 |
|
| Issue Date FY: 2021 ( Subtotal = $763,998 ) |
| | 2021 | 2021 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR STE 300, | ANN ARBOR | MI | 48108-9623 | WASHTENAW | USA | R44TR001324 | Fiber design and assessment for development of a novel biomimetic medical device | 001 | 3 | NIH | 9/8/2021 | $79,795 |
| | 2021 | 2021 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR STE 300, | ANN ARBOR | MI | 48108-9623 | WASHTENAW | USA | R44TR001324 | Fiber design and assessment for development of a novel biomimetic medical device | 000 | 3 | NIH | 7/29/2021 | $684,203 |
|
| Issue Date FY: 2020 ( Subtotal = $563,353 ) |
| | 2020 | 2020 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR STE 300 | ANN ARBOR | MI | 48108-9623 | WASHTENAW | USA | R44TR001324 | Fiber design and assessment for development of a novel biomimetic medical device | 000 | 2 | NIH | 8/13/2020 | $563,353 |
|
| Issue Date FY: 2019 ( Subtotal = -$221,086 ) |
| | 2019 | 2018 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR # 300 | ANN ARBOR | MI | 48108-9649 | WASHTENAW | USA | R01FD005092 | Phase 2 Study of Selective Cytopheretic Device for the Treatment of Pediatric Patients with Acute Kidney Injury | 000 | 3 | FDA | 8/2/2019 | -$177,778 |
| | 2019 | 2018 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR # 300 | ANN ARBOR | MI | 48108-9649 | WASHTENAW | USA | R01FD005092 | Phase 2 Study of Selective Cytopheretic Device for the Treatment of Pediatric Patients with Acute Kidney Injury | 001 | 3 | FDA | 8/7/2019 | -$43,308 |
|
| Issue Date FY: 2018 ( Subtotal = $398,864 ) |
| | 2018 | 2018 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR # 300 | ANN ARBOR | MI | 48108-9649 | WASHTENAW | USA | R01FD005092 | Phase 2 Study of Selective Cytopheretic Device for the Treatment of Pediatric Patients with Acute Kidney Injury | 000 | 3 | FDA | 4/11/2018 | $398,864 |
|
| Issue Date FY: 2017 ( Subtotal = $399,483 ) |
| | 2017 | 2017 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR # 300 | ANN ARBOR | MI | 48108-9649 | WASHTENAW | USA | R01FD005092 | Phase 2 Study of Selective Cytopheretic Device for the Treatment of Pediatric Patients with Acute Kidney Injury | 000 | 2 | FDA | 3/24/2017 | $399,483 |
| | 2017 | 2015 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR # 300 | ANN ARBOR | MI | 48108-9649 | WASHTENAW | USA | R43HL127830 | L-MOD Therapy: Leukocyte Immunomodulation during Cardiopulmonary Bypass | 000 | 1 | NIH | 11/22/2016 | $0 |
| | 2017 | 2015 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR # 300 | ANN ARBOR | MI | 48108-9649 | WASHTENAW | USA | R43TR001324 | Fiber design and assessment for development of a novel biomimetic medical device | 000 | 1 | NIH | 7/25/2017 | $0 |
| | 2017 | 2015 | INNOVATIVE BIOTHERAPIES, INC. | 650 AVIS DR # 300 | ANN ARBOR | MI | 48108-9649 | WASHTENAW | USA | R43HL118792 | Biomimetic Membrane Device for Therapeutic Application in Chronic Heart Failure | 000 | 1 | NIH | 7/26/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $0 ) |
| | 2016 | 2015 | INNOVATIVE BIOTHERAPIES INC | 650 AVIS DRIVE | ANN ARBOR | MI | 48108 | WASHTENAW | USA | R01FD005092 | Phase 2 Study of Selective Cytopheretic Device for the Treatment of Pediatric Patients with Acute Kidney Injury | 000 | 1 | FDA | 8/15/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $1,966,853 ) |
| | 2015 | 2015 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R43TR001324 | Fiber design and assessment for development of a novel biomimetic medical device | 000 | 1 | NIH | 7/15/2015 | $323,816 |
| | 2015 | 2015 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R43HL118792 | Biomimetic Membrane Device for Therapeutic Application in Chronic Heart Failure | 000 | 1 | NIH | 8/7/2015 | $655,205 |
| | 2015 | 2015 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R01FD005092 | Phase 2 Study of Selective Cytopheretic Device for the Treatment of Pediatric Patients with Acute Kidney Injury | 000 | 1 | FDA | 9/7/2015 | $399,132 |
| | 2015 | 2015 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R43HL127830 | L-MOD Therapy: Leukocyte Immunomodulation during Cardiopulmonary Bypass | 000 | 1 | NIH | 3/4/2015 | $588,700 |
|
| Issue Date FY: 2013 ( Subtotal = $1,057,332 ) |
| | 2013 | 2013 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R43DK097946 | IMMUNOMODULATORY DEVICE FOR TREATMENT OF PEDIATRIC ACUTE RENAL FAILURE PATIENTS | 000 | 1 | NIH | 7/11/2013 | $364,723 |
| | 2013 | 2013 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R44TR000630 | SELECTIVE CYTOPHERESIS THERAPY IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | 000 | 4 | NIH | 5/24/2013 | $692,609 |
|
| Issue Date FY: 2012 ( Subtotal = $739,631 ) |
| | 2012 | 2012 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R44TR000630 | SELECTIVE CYTOPHERESIS THERAPY IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | 000 | 3 | NIH | 9/8/2012 | $731,045 |
| | 2012 | 2012 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R44TR000630 | SELECTIVE CYTOPHERESIS THERAPY IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | 001 | 3 | NIH | 9/13/2012 | $8,586 |
|
| Issue Date FY: 2011 ( Subtotal = $1,052,792 ) |
| | 2011 | 2011 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R44DK082050 | ENHANCED PROPAGATION OF ADULT HUMAN RENAL EPITHELIAL CELLS ALLOWING FOR COMMERCIA | 001 | 3 | NIH | 8/17/2011 | $961,915 |
| | 2011 | 2010 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R44DK082050 | ENHANCED PROPAGATION OF ADULT HUMAN RENAL EPITHELIAL CELLS ALLOWING FOR COMMERCIA | 000 | 2 | NIH | 11/24/2010 | $90,877 |
|
| Issue Date FY: 2010 ( Subtotal = $1,583,913 ) (Continued on the next page) |
| | 2010 | 2010 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R44DK082050 | ENHANCED PROPAGATION OF ADULT HUMAN RENAL EPITHELIAL CELLS ALLOWING FOR COMMERCIA | 000 | 2 | NIH | 9/10/2010 | $1,100,657 |
| | 2010 | 2010 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R44DK074289 | CELL THERAPY FOR SEPTIC SHOCK | 002 | 4 | NIH | 4/1/2010 | $142,000 |
| | 2010 | 2009 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R44DK074289 | CELL THERAPY FOR SEPTIC SHOCK | 001 | 4 | NIH | 1/18/2010 | $74,106 |
| | 2010 | 2009 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R44DK074289 | CELL THERAPY FOR SEPTIC SHOCK | 003 | 4 | NIH | 5/28/2010 | $88,473 |
| | 2010 | 2009 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108 | WASHTENAW | USA | R44DK074289 | CELL THERAPY FOR SEPTIC SHOCK | 005 | 4 | NIH | 8/31/2010 | $0 |
| | 2010 | 2008 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108 | WASHTENAW | USA | R43DK082050 | ENHANCED PROPAGATION OF ADULT HUMAN RENAL EPITHELIAL CELLS | 000 | 1 | NIH | 1/4/2010 | $0 |
| | 2010 | 2008 | INNOVATIVE BIOTHERAPIES INC | 401 WEST MORGAN ROAD | ANN ARBOR | MI | 48108-9109 | WASHTENAW | USA | R44DK074289 | CELL THERAPY FOR SEPTIC SHOCK | 004 | 3 | NIH | 5/28/2010 | $106,729 |
|
